Macrocyclic spiroethers as Mcl-1 inhibitors

US11498928B2 · kind B2 · utility

Assignees

• ASCENTAGE PHARMA (SUZHOU) CO., LTD. · CN
• THE REGENTS OF THE UNIVERSITY OF MICHIGAN · US
• ASCENTAGE PHARMA GROUP CORP LIMITED · CN

Inventors

• Jianyong Chen · Tangxia, CN
• Yunlong Zhou · Suzhou, CN
• Guozhi Tang · Shanghai, CN
• Chengzhe Wu · Suzhou, CN
• Leilei Zhao · Suzhou, CN
• Lingling Jiao · Taizhou City, CN
• Binghua Sheng · Suzhou, CN
• Shaomeng Wang · Saline, US
• Chao-Yie Yang · Hangzhou City, CN
• Hao Chen · Columbia, US
• Wenliang Hu · Suzhou, CN
• Yu Jing · Suzhou, CN

Key dates

• Filing date: Jan 17, 2020
• Grant date: Nov 15, 2022
• Expiry date: Jan 17, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.